MARATTO

retraction · Canadian Journal of Physiology and Pharmacology

Retraction: Role and potential targeting of hepatic apurinic/apyrimidinic endonuclease-1 and cyclin-dependent kinase-4 in hepatocellular carcinoma

Abstract

Apurinic/apyrimidinic endonuclease/redox element 1 (APE1/Ref-1) is a pervasive multifunctional protein required in the DNA base extraction repair (BER) pathway and a noteworthy reducing-oxidizing (redox) factor that upgrades the authoritative of various transcription components to DNA. Cyclin-dependent kinases (CDKs) assume a key part in directing the movement of the cell-cycle. The present study evaluates the synergistic efficacy of using licochalcone B (LCB) and fullerene C60 (FnC60) nanoparticles against diethylnitrosamine (DEN)-induced hepatocarcinoma (HCC) in rats. The results indicated that LCB alone and in combination with FnC60 significantly decreased the percent of DNA fragmentation, oxidative DNA damage byproduct (8-OH-2dG) and the mRNA expression of APE1/Ref-1, CDK-4, retinoblastoma (Rb), B-cell lymphoma-2 (Bcl-2), B-cell lymphoma-xL (Bcl-xL), and β-arrestin-2 along with decreased protein expression of APE1/Ref-1 and CDK-4; whereas these treatments significantly increased the expression of prot...

Research topics

  • PARP inhibition in cancer therapy
  • Cancer therapeutics and mechanisms
  • Calcium signaling and nucleotide metabolism

Read the original research

This page summarises published work. The authoritative version sits with the publisher.

DOI: 10.1139/cjpp-2018-0071

Is something wrong with this record? Report it or request removal.

Discussion

Discuss this research

Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.

No discussion yet. Open the first thread.